Combining radiation, immunotherapy, and chemotherapy for high-risk rectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of radiation, immunotherapy (a drug that helps your immune system fight cancer), and chemotherapy before surgery for high-risk rectal cancer that has not spread. It aims to improve the chance of shrinking or eliminating the tumor before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a type of rectal cancer called adenocarcinoma that has not spread to distant organs.
- Your cancer is considered high-risk, meaning it is locally advanced (for example, it is deep, involves nearby lymph nodes, or touches surrounding tissue).
- The lower edge of your tumor is within 10 cm of the anal opening.
- You have not had any prior cancer treatment (such as surgery, radiation, or chemotherapy) for this rectal cancer.
- You are generally well enough to carry out daily activities (performance status 0–1) and your blood counts and organ function are within the required limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment plan involving radiation, chemotherapy, and an immunotherapy drug (a PD-1 inhibitor) for people with a specific type of high-risk rectal cancer. The goal is to see if this combination helps shrink the tumor before surgery.
This trial tests a new approach for people with locally advanced rectal cancer that has high-risk features. It combines short-course radiation with chemotherapy (CapeOX) and the immunotherapy drug toripalimab, with or without another drug called surufatinib, before surgery. The goal is to see if adding these drugs helps shrink the tumor and improve outcomes.
This study tests a combination of radiation therapy, chemotherapy drugs (capecitabine and oxaliplatin), and two types of immunotherapy (a PD-1 blocker and IL-2) for locally advanced rectal cancer. The goal is to see if this combination helps shrink tumors and improve outcomes before surgery.
This trial tests a combination of brief radiation therapy followed by immunotherapy and chemotherapy for locally advanced rectal cancer that hasn't spread. The goal is to see if this approach helps patients avoid or reduce surgery while controlling their cancer.
This trial tests if adding immunotherapy to standard chemotherapy and radiation before surgery helps shrink high-risk rectal cancer and prevent it from coming back. You may be a good fit if you have a specific type of advanced rectal cancer that hasn't spread to other parts of your body.
This trial tests a new treatment sequence for locally advanced rectal cancer: a short course of radiation followed by a combination of immunotherapy (cadonilimab) and chemotherapy (mFOLFOX6) before surgery. The goal is to shrink the tumor more effectively and potentially improve outcomes.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.